posted
IRVINE, Calif., April 18 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today announced that revenues for 2006 totaled $1.25 million, down slightly from revenues of $1.29 million in 2005. The Company announced a gross profit of $662,713 in 2006 and net income of $13,800 compared to a loss of $(5.0) million in 2005. ADVERTISEMENT
The net income reported is because of the unrealized gain on adjustment of derivative and warrant liabilities to fair value of the underlying securities relating to the convertible notes CalbaTech obtained in 2005, as well as CalbaTech's continuing efforts to control expenses.
CalbaTech's reagent division provides general laboratory supplies to a $14 billion market and products and services for medical research and drug discovery. The Company projects revenues of $1.6 million from this division in 2007.
CalbaTech also projected that revenues from its LifeStem subsidiary could top $3.9 million in the twelve months beginning in the second quarter of 2007.
"The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis may revolutionize the practice of medicine," CalbaTech said in its 10K filing. "The power and promise of stem cell therapies is just emerging, and the corresponding development of new clinical applications and therapies are expected to follow. LifeStem's Stem Cell Microbank(TM) Service focuses on refining existing collection processes that are gaining significant acceptance. The focus will be providing a stem cell collection process and storage service that maintains adult stem cells for future use and broadens the availability of a collection and storage service. While some of the regulatory, logistical and training issues have taken longer than anticipated, this is to be expected in a new breakthrough service such as ours. We have, however, recently received the necessary licenses from the State of California and are moving the Service forward as fast as possible."
"The MicroBanking process, for which LifeStem has filed for US patent protection, is based on the theory that it is not necessary to harvest a quantity of stem cells capable of regenerating the entire immune system at the time of collection, but rather that these cells can be collected in micro quantities and cryo-preserved for future cellular expansion prior to reintroduction into the recipient."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells in micro quantities to be cryo-preserved for future transplantation into a client for medical purposes. The collection of stem cells from two different tissue sources increases the potential for treatment of more diseases.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
